HALO
Oof, that’s not the kind of quarter you frame on the wall
Halozyme’s fourth-quarter 2025 results came in like a product launch with the lights off: adjusted loss of 24 cents per share, when Wall Street was looking for a $2.15 profit. Compared with $1.26 in adjusted earnings a year ago, that’s a pretty nasty swing, and the stock has clearly been feeling the pain.
The good news is hiding in the royalties
This wasn’t a story of the top line falling apart. Halozyme said royalty revenues hit $258 million in the quarter, up 51% year over year. That boost came from strong demand for Phesgo, subcutaneous Darzalex, and Vyvgart Hytrulo — basically, the company’s royalty engine was still humming even while the bottom line face-planted.
So what broke the math?
The culprit was an unfavorable $2.42 per share hit tied to acquired IPR&D expense from the Surf Bio acquisition. Translation: Halozyme took a big accounting and deal-related hit that mashed the quarter’s earnings like a thumb on a car door.
Why investors should care
If you own HALO, the question isn’t just “was this quarter bad?” It’s “was this a one-time stumble or a sign the company’s acquisition strategy is getting pricey?” Strong royalty growth is nice, but markets usually care most about the part of the business that eventually turns into actual profit.
Big picture: Halozyme still has a healthy royalty story, but this quarter reminded investors that deal costs can crash the party fast.